Signature Rx, Delray Beach, FL
Is Signature Rx registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Signature Rx in Delray Beach, FL, first registered Oct 13, 2023 and most recently registered Aug 31, 2026.
Does Signature Rx hold a Florida pharmacy license?
The Florida Board of Pharmacy lists license PH34791 for SIGNATURE RX, INC (dba Signature Rx), DELRAY BEACH, status Clear, as of Nov 15, 2026.
Has Signature Rx had a state board action or FDA letter?
FDA letters: no matching record found. No entry for Signature Rx was matched by name and location on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026. State board actions: no Florida Board of Pharmacy action on license PH34791 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Signature Rx
- Location
- Delray Beach, FL
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as Signature Rx
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- None listed
- FDA Data Dashboard inspections
- No matching site found
- State board records
- License found: PH34791, Clear
FDA inspections and letters
No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH34791 | Pharmacy | SIGNATURE RX, INC (dba Signature Rx) | DELRAY BEACH | Clear |
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
FDA’s 503B list
- Signature Rx, Delray Beach, FL: last inspection not yet inspected, Form 483 at that inspection: N/A, action FDA lists: N/A.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Signature Rx”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 84582-4104 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 4 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.